Key result
Lower circulating ceramides and S1P linked to greater likelihood of myocardial recovery post-LVAD.
Why the study?
Are sphingolipid levels associated with myocardial recovery in advanced heart failure patients after LVAD support?
Observational
Are sphingolipid levels associated with myocardial recovery in advanced heart failure patients after LVAD support?
Answers are grounded in this paper and cite their sources.
Diminished ceramide and S1P levels may be associated with an increased likelihood of myocardial recovery after LVAD support, suggesting the sphingolipid metabolic pathway as a potential therapeutic target.
Myocardial recovery after left ventricular assist device (LVAD) support is a critical phenomenon that allows advanced heart failure patients to retain their native heart. We quantified targeted sphingolipids in serum and cardiac tissue of patients who exhibited recovery post-LVAD. Our analysis revealed sustained elevated circulating ceramides levels in nonresponders post-LVAD, whereas responders showed reduced sphingosine-1-phosphate (S1P) levels. In contrast, cardiac tissue from nonresponders displayed increased S1P levels. We suggest that diminished ceramide and S1P may contribute to an increased likelihood of recovery after LVAD support. Collectively, our findings implicate the sphingolipid metabolic pathway as a potential therapeutic target to promote myocardial recovery after mechanical support.
No takes yet. Share an insight, caveat, or question.
Hamouche et al. (2025) conducted an observational in Advanced heart failure post-LVAD. Sphingolipid levels (ceramides and S1P) vs. Responders vs nonresponders was evaluated on Myocardial recovery post-LVAD. Diminished circulating ceramide and sphingosine-1-phosphate (S1P) levels were associated with an increased likelihood of myocardial recovery after LVAD support in advanced heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: